|Last Price||Today's Change||52-Week Range||Trading Volume|
|57.29||0.00 (0.00%)||52.49 - 63.62||222.0 thousand (Below Avg)|
Market data as of 12:00AM 06/29/15. Quotes are delayed by at least 15 min.
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
06/29/2015 8:30 AM ET
Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
06/26/2015 8:00 AM ET